|
1
|
Samraj GP: Vildagliptin for the treatment
of diabetes. Therapy. 8:703–719. 2011. View Article : Google Scholar
|
|
2
|
Croxtall JD and Keam SJ: Vildagliptin: a
review of its use in the management of type 2 diabetes mellitus.
Drugs. 68:2387–2409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Masuda K, Aoki K and Terauchi Y: Effects
of miglitol taken just before or after breakfast on plasma glucose,
serum insulin, glucagon and incretin levels after lunch in men with
normal glucose tolerance, impaired fasting glucose or impaired
glucose tolerance. J Diabet Invest. 2:435–440. 2011. View Article : Google Scholar
|
|
4
|
Aoki K, Kamiyama H, Yoshimura K, Shibuya
M, Masuda K and Terauchi Y: Miglitol administered before breakfast
increased plasma active glucagon-like peptide-1 (GLP-1) levels
after lunch in patients with type 2 diabetes treated with
sitagliptin. Acta Diabetol. 49:225–230. 2012. View Article : Google Scholar
|
|
5
|
Narita T, Katsuura Y, Sato T, et al:
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and
reduced gastric inhibitory polypeptide response after ingestion of
a mixed meal in Japanese Type 2 diabetic patients. Diabet Med.
26:187–188. 2009. View Article : Google Scholar
|
|
6
|
Arakawa M, Ebato C, Mita T, et al:
Miglitol suppresses the postprandial increases in interleukin 6 and
enhances active glucagon-like peptide 1 secretion in viscerally
obese subjects. Metabolism. 57:1299–1306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aoki K, Miyazaki T, Nagakura J, Orime K,
Togashi Y and Terauchi Y: Effects of pre-meal versus post-meal
administration of miglitol on plasma glucagon-like peptide-1 and
glucose dependent insulinotropic polypeptide levels in healthy men.
Endocr J. 57:673–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pi-Sunyer FX, Schweizer A, Mills D and
Dejager S: Efficacy and tolerability of vildagliptin monotherapy in
drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract.
76:132–138. 2007.PubMed/NCBI
|
|
9
|
Tahrani AA, Piya MK and Barnett AH: Drug
evaluation: vildagliptin-metformin single-tablet combination. Adv
Ther. 26:138–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahrén B: Clinical results of treating type
2 diabetic patients with sitagliptin, vildagliptin or saxagliptin -
diabetes control and potential adverse events. Best Pract Res Clin
Endocrinol Metab. 23:487–498. 2009.PubMed/NCBI
|
|
11
|
Bosi E, Dotta F, Jia Y and Goodman M:
Vildagliptin plus metformin combination therapy provides superior
glycaemic control to individual monotherapy in treatment-naive
patients with type 2 diabetes mellitus. Diabetes Obes Metab.
11:506–515. 2009. View Article : Google Scholar
|
|
12
|
Devendra D, Gohel B, Bravis V, et al:
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes
patients during Ramadan. Int J Clin Pract. 63:1446–1450. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matthews DR, Dejager S, Ahren B, et al:
Vildagliptin add-on to metformin produces similar efficacy and
reduced hypoglycaemic risk compared with gimepiride, with no weight
gain: results from a 2-year study. Diabetes Obes Metab. 12:780–789.
2010.PubMed/NCBI
|
|
14
|
Iwamoto Y, Kashiwagi A, Yamada N, et al:
Efficacy and safety of vildagliptin and voglibose in Japanese
patients with type 2 diabetes: a 12-week, randomized, double-blind,
active-controlled study. Diabetes Obes Metab. 12:700–708. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schweizer A, Dejager S, Foley JE, Shao Q
and Kothny W: Clinical experience with vildagliptin in the
management of type 2 diabetes in a patient population ≥ 75 years: a
pooled analysis from a data base of clinical trials. Diabetes Obes
Metab. 13:55–64. 2011.PubMed/NCBI
|
|
16
|
Ligueros-Saylan M, Foley JE, Schweizer A,
Couturier A and Kothny W: An assessment of adverse effects of
vildagliptin versus comparators on the liver, the pancreas, the
immune system, the skin and in patients with impaired renal
function from a large pooled database of Phase II and III clinical
trials. Diabetes Obes Metab. 12:495–509. 2010. View Article : Google Scholar
|
|
17
|
Richard KR, Shelburne JS and Kirk JK:
Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin
Ther. 33:1609–1629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kahn SE, Haffner SM, Heise MA, et al:
Glycemic durability of rosiglitazone, metformin, or glyburide
monotherapy. N Engl J Med. 355:2427–2443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dormandy JA, Charbonnel B, Eckland DJ, et
al: Secondary prevention of macrovascular events in patients with
type 2 diabetes in the PROactive study (PROspective pioglitAzone
Clinical Trial In macroVascular Events): a randomised controlled
trial. Lancet. 366:1279–1289. 2005. View Article : Google Scholar
|
|
20
|
Ilag LL, Kerr L, Malone JK and Tan MH:
Prandial premixed insulin analogue regimens versus basal insulin
analogue regimens in the management of type 2 diabetes: an
evidence-based comparison. Clin Ther. 29:1254–1270. 2007.
View Article : Google Scholar
|
|
21
|
Neumiller JJ: Differential chemistry
(structure), mechanisnm faction, and pharmacology of GLP-1 receptor
agonists and DPP-4 inhibitor. J Am Pharm Assoc (2003). 49(Suppl 1):
S16–S29. 2009. View Article : Google Scholar : PubMed/NCBI
|
